Navigation Links
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2009 Financial Results Conference Call
Date:7/23/2009

CARLSBAD, Calif., July 23 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

    What:       Isis Pharmaceuticals' Second Quarter 2009 Financial Results

    When:       Thursday, August 6, 2009 at 8:30 a.m. ET / 5:30 a.m. PT

    Where:      www.isispharm.com

    How:        Live on the Internet.  Simply log onto our Web site listed above.

    Contacts:   Kristina Lemonidis
                Director, Investor Relations
                (760) 603-2490

                Amy Blackley, Ph.D.
                Assistant Director, Corporate Communications
                (760) 603-2772

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is a
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. NHP Announces Second Quarter Earnings Release Date and Webcast/Conference Call
2. ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2009 Results
3. CorVel Announces Earnings Release Webcast
4. Kendle Announces Details Regarding Second Quarter 2009 Earnings Conference Call and Webcast
5. Smart Balance to Host Webcast/Conference Call on 2009 Second-Quarter Results
6. Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast
7. NBTY to Webcast Presentation at Oppenheimer 9th Annual Consumer, Gaming, Lodging & Leisure Conference; Announces Fiscal Third Quarter Preliminary Unaudited Net Sales Results
8. Boston Scientific to Webcast Conference Call Discussing Second Quarter Financial Results
9. Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2009 Financial Results Conference Call
10. Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast
11. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. Announces Second Quarter 2009 Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)NEW ORLEANS, Dec. 5 There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in orde
(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int
(Date:12/5/2009)AVIVA today announced the launch of International Solutions, an innovative new international private medical insurance plan which follows the acclaimed modular design of its UK equivalent. In addition
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
Breaking Medicine News(10 mins):Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2
...sychologists have found in a study that instead of...how one feels about their body shape and thereby a...ies the way they are end up with the lowest body m...ology and one of the researchers said that eating ...
...abeling mix-up among about 135 people, whose blood...d to a re-test among 90 people as one of the patie...test in April. The pathology center has conc...hs without knowing it. The mix-up was reveal...
...o assess the economic impact of air quality change...re found to be second only to timber losses in ter...ished in the Canadian Journal of Forest Research, ...imates the effects in terms of health risk to be b...
... in mice has found that though they do not develop...ty researchers were able to differentiate the cell...or the oily skin. The research examines how a seba...t Rockefeller University, settles this argument, s...
...ity Improvement Scotland (QIS) review of the perfo... in 2003 for food, fluid and nutritional care find... The NHS Quality Improvement Scotland had iss...dmitted following concerns about the number of und...
...essive amounts of soda and sugary drinks is making...iew.// Frank Hu and his colleagues at the Har...dible scientific nutrition studies conducted over ...erages account for half of those calories, reporte...
Other Medicine News:Health News:Study Finds Healthier Women Are Those Who Accept The Way They Look 2Health News:'Blimp1' Gene Linked To Oily Skin 2
(Date:12/4/2009)Opposes use of imported drugs often stored in tin cans and car trunks ,, WASHINGTON, Dec. 4 Today, the senior advocacy group RetireSafe urged the Senate to defeat the Dorgan Importation plan encomp
(Date:12/4/2009)HOUSTON, Dec. 4 OrthoAccel Technologies, Inc., developers of the AcceleDent System , which is an acceleration device to enhance orthodontics, announced the availability of a new Continuing Education
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC Bulletin Board: NWBO) announced today that the US Patent and Trademark Office has allowed its patent application o
Breaking Medicine Technology:RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgan's Drug Importation Plan Puts Seniors at Risk 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5For gay and straight men facial attraction operates similarly 60412 1For gay and straight men facial attraction operates similarly 60412 2MedImmune to present 4 abstracts on RSV and influenza at 47TH Annual IDSA Meeting 60410 1MedImmune to present 4 abstracts on RSV and influenza at 47TH Annual IDSA Meeting 60410 2MedImmune to present 4 abstracts on RSV and influenza at 47TH Annual IDSA Meeting 60410 3ESC events in Asia tackle management of diabetes and cardiovascular disease 60408 1ESC events in Asia tackle management of diabetes and cardiovascular disease 60408 2ESC events in Asia tackle management of diabetes and cardiovascular disease 60408 3
...Rates of MACE with XIENCE V -, CHICAGO, March 31 ...ical trial demonstrated continued positive clinica...Coronary Stent System out,to two years, including ...cardiac events (MACE) and an observed 44 percent r...rget lesion revascularization, TLR) compared,to th...
...M) Stents demonstrate positive ...CAGO, March 31 Boston,Scientific Corporation (NYS...,from Abbott,s prospective, randomized (3:1), sing...g the safety and efficacy of the XIENCE(TM) V,(PRO...ton Scientific,s,worldwide market-leading TAXUS(R)...
Other Medicine Technology:Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years 2Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years 3Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms 2Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms 3Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms 4
5F Infiniti
Softtouch
CT Micro Stereotactic System
Tapered Tefcor Movable Core Wire Guides
Medicine Products: